PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
|Videos|June 23, 2011
Dr. Infante on the Next Step in Melanoma Research
Author(s)Jeffrey R. Infante, MD
Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research
Advertisement
Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute on the next step in melanoma research.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5